Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 7/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | SRC | P12931 | 5/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.45 |
| ▸ | SIK1 | P57059 | 2/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.40 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 2/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495232 | 0.94 | LCK (0.43) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4510853 | 0.93 | LCK (0.51) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4496978 | 0.93 | LCK (0.52) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL5689208 | 0.90 | LCK (0.47) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4504458 | 0.89 | LCK (0.50) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL5686310 | 0.89 | LCK (0.55) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4496675 | 0.89 | BTK (0.46) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL4509428 | 0.88 | LCK (0.50) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL5686194 | 0.87 | LCK (0.47) | LCKTNK2BTKJAK3KDR | |
| SCHEMBL5689088 | 0.87 | LCK (0.48) | LCKTNK2BTKJAK3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | claimed |
| EP-1648464-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AMGEN INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009443-A1 | 2-AMINO-4-HYDROXY-5-PYRIMIDINECARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF T CELL ACTIVATION FOR THE TREATMENT OF INFLAMMATORY DISEASES | AMGEN INC. (US) | 2005-02-03 | — | — | WO | disclosed |